NCT06284590
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06284590
Title Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients (INTACT/MeRCI)
Acronym INTACT/MeRCI
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Philogen S.p.A.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | DEU

Facility Status City State Zip Country Details
Hartford Hospital RECRUITING Hartford Connecticut 06102 United States Details
Memorial Sloan Kettering Cancer Center RECRUITING New York New York 10065 United States Details
Universitätsklinikum Essen RECRUITING Essen Germany 45147 Germany Details
University of Freiburg, Faculty of Medicine RECRUITING Freiburg im Breisgau Germany 79104 Germany Details
University Hospital Schleswig-Holstein NOT_YET_RECRUITING Kiel Germany 24105 Germany Details
University Hospital Tuebingen NOT_YET_RECRUITING Tübingen Germany 72076 Germany Details
IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale" RECRUITING Naples Campania 80131 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field